{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:53:21Z","timestamp":1780340001952,"version":"3.54.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.euf.2019.03.011","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T23:52:12Z","timestamp":1553298732000},"page":"14-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8298-0289","authenticated-orcid":false,"given":"Bradley A.","family":"McGregor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru P.","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2019.03.011_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"1","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euf.2019.03.011_bib0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2018.09.010","article-title":"An open-label randomized phase 2 study of durvalumab alone or in combination with tremelimumab in patients with advanced germ cell tumors (APACHE): results from the first planned interim analysis","volume":"75","author":"Necchi","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.03.011_bib0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.euf.2019.03.011_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-015-0047-3","article-title":"Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study","volume":"3","author":"Fay","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euf.2019.03.011_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euf.2019.03.011_bib0030","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2019.03.011_bib0035","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00345-016-1898-z","article-title":"Platinum-refractory germ cell tumors: an update on current treatment options and developments","volume":"35","author":"Oing","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2019.03.011_bib0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2019.03.011_bib0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fphar.2016.00487","article-title":"Prognostic and predictive factors in patients with advanced penile cancer receiving salvage (2nd or later line) systemic treatment: a retrospective, multi-center study","volume":"7","author":"Buonerba","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.euf.2019.03.011_bib0050","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/CJI.0000000000000221","article-title":"Evidence for efficacy of treatment with the anti-PD-1 Mab nivolumab in radiation and multichemorefractory advanced penile squamous cell carcinoma","volume":"41","author":"Trafalis","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.euf.2019.03.011_bib0055","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.5489\/cuaj.1195","article-title":"Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer","volume":"3","author":"Chalasani","year":"2009","journal-title":"Can Urol Assoc J"},{"issue":"Suppl. 7","key":"10.1016\/j.euf.2019.03.011_bib0060","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.2019.37.7_suppl.479","article-title":"Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs)","volume":"37","author":"Agarwal","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456919300860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456919300860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:49:37Z","timestamp":1762498177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456919300860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S2405456919300860"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2019.03.011","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2019.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}